How to buy Sutro Biopharma stock (STRO)

Sutro Biopharma is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.89 – an increase of 0.53% over the previous week. Sutro Biopharma employs 302 staff and has a trailing 12-month revenue of around $161 million.

Our top picks for where to buy Sutro Biopharma stock

Buy Sutro Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sutro Biopharma stock price (NASDAQ: STRO)

Use our graph to track the performance of STRO stocks over time.

Sutro Biopharma shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.89
52-week range	$1.70 - $6.13
50-day moving average more info button	$3.04
200-day moving average more info button	$3.70
Wall St. target price	$11.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.55

Is it a good time to buy Sutro Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sutro Biopharma price performance over time

Historical closes compared with the close of $1.97 from 2024-12-26

1 week (2024-12-20)	4.79%
1 month (2024-11-29)	-25.66%
3 months (2024-09-27)	-43.71%
6 months (2024-06-28)	-32.76%

1 year (2023-12-28)	-54.82%
2 years (2022-12-28)	-72.37%
3 years (2021-12-28)	15.47
5 years (2019-12-27)	10.98

Sutro Biopharma financials

Revenue TTM	$161 million
Gross profit TTM	$-42,520,000
Return on assets TTM	-18.4%
Return on equity TTM	-110.89%
Profit margin	-77.01%
Book value	$1.82
Market Capitalization more info button	$162.4 million

TTM: trailing 12 months

Sutro Biopharma share dividends

We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.

Sutro Biopharma share price volatility

Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $1.7 up to $6.13. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 1.168. This would suggest that Sutro Biopharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Sutro Biopharma overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co.

Frequently asked questions

What percentage of Sutro Biopharma is owned by insiders or institutions?
Currently 0.976% of Sutro Biopharma shares are held by insiders and 77.139% by institutions. How many people work for Sutro Biopharma?
Latest data suggests 302 work at Sutro Biopharma. When does the fiscal year end for Sutro Biopharma?
Sutro Biopharma's fiscal year ends in December. Where is Sutro Biopharma based?
Sutro Biopharma's address is: 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is Sutro Biopharma's ISIN number?
Sutro Biopharma's international securities identification number is: US8693671021 What is Sutro Biopharma's CUSIP number?
Sutro Biopharma's Committee on Uniform Securities Identification Procedures number is: 869367102